At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
RXC004 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Modular Multi-Arm, Phase 1, Adaptive Design Study to Evaluate the Safety and Tolerability of RXC004, Alone and in Combination With Anti-cancer Treatments, in Patients With Advanced Malignancies
In Brief
A Phase 1 clinical trial evaluating RXC004 and Nivolumab for Cancer and Solid Tumor. Completed, enrolled 46 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine the safety and tolerability of RXC004 as monotherapy and in combination with Nivolumab in patients with advanced malignancies. In order to define the doses and schedules for further clinical evaluation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Solid Tumor
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMar 2019
Primary CompletionSep 2023
TodayJul 2026
First PostedFeb 27, 2018
Enrollment StartMar 18, 2019
Primary CompletionSep 29, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.3 years ago
Interventions
RXC004drug
RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
Nivolumabdrug
RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway. Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1